Greenrose Holding Co Inc. Stock: price and directors' dealings · United States · SEC (Form 4)

About Greenrose Holding Co Inc.

The Greenrose Holding Company Inc. is a U.S.-based company historically exposed to the medical cannabis and cannabinoid-products market. The most recent market profile data reviewed describes the company as founded in 2014 and headquartered in Amityville, New York, United States. Its operating footprint was built through subsidiaries involved in cultivating, processing, packaging, and selling medical cannabis and derivative products. In other words, Greenrose was structured around a vertically integrated cannabis model, aiming to control more of the value chain from production to finished products and downstream commercialization. ([stockanalysis.com](https://stockanalysis.com/quote/otc/GNRSQ/company/)) From an equity analyst perspective, Greenrose has operated in a niche industry defined by heavy regulation, high execution risk, and a fragmented competitive landscape. In this type of business, competitive positioning typically depends on licensing, compliance, cultivation efficiency, product quality, and the ability to maintain stable retail or wholesale channels. Greenrose’s historical niche was medical cannabis rather than a diversified pharmaceutical platform, so its risk profile has been materially tied to the regulatory environment for cannabis in the United States, operating leverage in cultivation and processing, and access to capital. ([stockanalysis.com](https://stockanalysis.com/quote/otc/GNRSQ/company/)) A critical recent development is that The Greenrose Holding Company Inc. filed a voluntary petition for liquidation under Chapter 7 on June 18, 2024, in the U.S. Bankruptcy Court for the Eastern District of New York. That filing changes the investment case substantially. Instead of a normal operating-growth story, the company should now be viewed as a distressed or liquidation-stage situation, with limited forward visibility on ordinary business performance. For investors tracking SEC Form 4 insider activity, that context matters: insider transactions should be interpreted against the backdrop of bankruptcy proceedings and a much weaker capital-structure profile. ([stockanalysis.com](https://stockanalysis.com/quote/otc/GNRSQ/company/)) On the market side, the latest profile reviewed shows GNRSQ quoted on the OTC Markets rather than on the NYSE or NASDAQ. So while the company is a U.S. issuer, it is not currently presented as a mainstream large-cap or mid-cap exchange-listed name. Its geographical footprint has remained U.S.-centric, with Amityville, New York listed as the headquarters and no meaningful international operating presence indicated in the sources reviewed. For French-speaking investors in France, Belgium, or Switzerland, the key takeaway is that Greenrose is best understood as a highly speculative U.S. cannabis-related situation with significant legal and financial overhangs, rather than as a conventional listed consumer-health or pharmaceutical business. ([stockanalysis.com](https://stockanalysis.com/quote/otc/GNRSQ/company/))